Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFL-102
- Development stage
- Unknown
- Lead developer
- NFL Biosciences
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
NFL-102 is a botanical drug candidate being developed by NFL Biosciences for the treatment of tobacco and nicotine addiction. It is composed of a nicotine-depleted tobacco protein extract. The mechanism of action involves the modulation of the CREB (cAMP response element-binding protein), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and JNK (c-Jun N-terminal kinase) signaling pathways, which are associated with the neurobiological processes of addiction. NFL-102 is designed to support smoking cessation by potentially reducing nicotine reinforcement and withdrawal symptoms. As of early 2026, the program is positioned in Phase 2 development, with the company preparing to file a Phase 2b clinical trial application in mid-2026.
- Other names
- nicotine-depleted tobacco protein extract
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)NF-κBCREB (Cyclic AMP response element-binding protein)
Beyond the preview
Go deeper on NFL-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFL-102.